Salzman Capital Ventures

Salzman Capital Ventures is a life sciences venture capital and drug development firm that operates as an incubator for novel therapeutic technologies. Founded and led by Dr. Andrew Salzman, the company focuses on the discovery and advancement of small molecule drugs targeting complex pathways in inflammation, oxidative stress, and DNA repair. The firm's primary research programs involve the development of potent PARP inhibitors and catalytic antioxidant mimetics, such as metalloporphyrins, for indications ranging from ischemia-reperfusion injury to acute lung injury. Salzman Capital Ventures leverages its internal R&D capabilities, often through its affiliate Salzman Group, to progress assets from early discovery through clinical proof-of-concept. The company is known for its expertise in medicinal chemistry and its strategic focus on high-unmet-need medical conditions.